Caveolin-1 Expression Is Critical for Vascular Endothelial Growth Factor–Induced Ischemic Hindlimb Collateralization and Nitric Oxide–Mediated Angiogenesis

Nitric oxide (NO) is a powerful angiogenic mediator acting downstream of vascular endothelial growth factor (VEGF). Both the endothelial NO synthase (eNOS) and the VEGFR-2 receptor colocalize in caveolae. Because the structural protein of these signaling platforms, caveolin, also represses eNOS activity, changes in its abundance are likely to influence the angiogenic process in various ways. In this study, we used mice deficient for the caveolin-1 gene (Cav−/−) to examine the impact of caveolae suppression in a model of adaptive angiogenesis obtained after femoral artery resection. Evaluation of the ischemic tissue perfusion and histochemical analyses revealed that contrary to Cav+/+ mice, Cav−/− mice failed to recover a functional vasculature and actually lost part of the ligated limbs, thereby recapitulating the effects of the NOS inhibitor l-NAME administered to operated Cav+/+ mice. We also isolated endothelial cells (ECs) from Cav−/− aorta and showed that on VEGF stimulation, NO production and endothelial tube formation were dramatically abrogated when compared with Cav+/+ ECs. The Ser1177 eNOS phosphorylation and Thr495 dephosphorylation but also the ERK phosphorylation were similarly altered in VEGF-treated Cav−/− ECs. Interestingly, caveolin transfection in Cav−/− ECs redirected the VEGFR-2 in caveolar membranes and restored the VEGF-induced ERK and eNOS activation. However, when high levels of recombinant caveolin were reached, VEGF exposure failed to activate ERK and eNOS. These results emphasize the critical role of caveolae in ensuring the coupling between VEGFR-2 stimulation and downstream mediators of angiogenesis. This study also provides new insights to understand the paradoxical roles of caveolin (eg, repressing basal enzyme activity but facilitating activation on agonist stimulation) in cardiovascular pathophysiology.

[1]  A. Y. Wu,et al.  Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. , 1999, Circulation research.

[2]  K. Iwatsubo,et al.  Accumulation of molecules involved in alpha1-adrenergic signal within caveolae: caveolin expression and the development of cardiac hypertrophy. , 2001, Cardiovascular research.

[3]  J. Balligand,et al.  Hsp90 and Caveolin Are Key Targets for the Proangiogenic Nitric Oxide–Mediated Effects of Statins , 2001, Circulation research.

[4]  David S. Park,et al.  Caveolin-1 Expression Enhances Endothelial Capillary Tubule Formation* , 2002, The Journal of Biological Chemistry.

[5]  M. Drab,et al.  Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted Mice , 2001, Science.

[6]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[7]  I. Yuhanna,et al.  Oxidized Low Density Lipoprotein Displaces Endothelial Nitric-oxide Synthase (eNOS) from Plasmalemmal Caveolae and Impairs eNOS Activation* , 1999, The Journal of Biological Chemistry.

[8]  J. Engelman,et al.  Caveolin‐mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo , 1998, FEBS letters.

[9]  K. Sandvig,et al.  Caveolae: anchored, multifunctional platforms in the lipid ocean. , 2003, Trends in cell biology.

[10]  J. Balligand,et al.  Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. , 1999, The Journal of clinical investigation.

[11]  S. Woodman,et al.  Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. , 2003, The American journal of pathology.

[12]  G. Christ,et al.  Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. , 2001, The Journal of biological chemistry.

[13]  S. Vatner,et al.  Downregulation of caveolin by chronic β-adrenergic receptor stimulation in mice. , 1997, American journal of physiology. Cell physiology.

[14]  D. Kass,et al.  Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. , 2000, Circulation research.

[15]  O. Frazier,et al.  Mechanical unloading increases caveolin expression in the failing human heart. , 2003, Cardiovascular research.

[16]  J. Balligand,et al.  Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. , 2003, Cardiovascular research.

[17]  R. Kelly,et al.  The caveolar paradox: suppressing, inducing, and terminating eNOS signaling. , 2001, Circulation research.

[18]  S. Woodman,et al.  Caveolae: From Cell Biology to Animal Physiology , 2002, Pharmacological Reviews.

[19]  M. Lisanti,et al.  Angiogenesis Activators and Inhibitors Differentially Regulate Caveolin-1 Expression and Caveolae Formation in Vascular Endothelial Cells , 1999, The Journal of Biological Chemistry.

[20]  David S. Park,et al.  Caveolin, Caveolae, and Endothelial Cell Function , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[21]  J. Balligand,et al.  Rosuvastatin Decreases Caveolin-1 and Improves Nitric Oxide–Dependent Heart Rate and Blood Pressure Variability in Apolipoprotein E−/− Mice In Vivo , 2003, Circulation.

[22]  P. Huang,et al.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.

[23]  L. Kobzik,et al.  Endothelial Nitric Oxide Synthase Targeting to Caveolae , 1996, The Journal of Biological Chemistry.

[24]  R. Sercombe,et al.  Caveolin-1 and -3 dissociations from caveolae to cytosol in the heart during aging and after myocardial infarction in rat. , 2003, Cardiovascular research.

[25]  T. Guarnieri,et al.  Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. , 2000, Biochemical and biophysical research communications.

[26]  P. Massart,et al.  Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy. , 2002, American journal of physiology. Heart and circulatory physiology.

[27]  P. Gallagher,et al.  Increased numbers of caveolae in retinal endothelium and pericytes in hypertensive diabetic rats , 2001, Eye.

[28]  R. Groszmann,et al.  Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. , 2003, Cancer cell.

[29]  J. Ross,et al.  Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. , 1998, Circulation.

[31]  D. Gingras,et al.  Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. , 2003, Molecular biology of the cell.

[32]  Yi Zhu,et al.  Lipoprotein Promotes Caveolin-1 and Ras Translocation to Caveolae: Role of Cholesterol in Endothelial Signaling , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[33]  T. Michel,et al.  The Endothelial Nitric-oxide Synthase-Caveolin Regulatory Cycle* , 1998, The Journal of Biological Chemistry.

[34]  J. Isner,et al.  Age-dependent impairment of angiogenesis. , 1999, Circulation.

[35]  Jean-Luc Balligand,et al.  Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. , 2003, Cancer research.

[36]  J. Balligand,et al.  Hsp90 Ensures the Transition from the Early Ca2+-dependent to the Late Phosphorylation-dependent Activation of the Endothelial Nitric-oxide Synthase in Vascular Endothelial Growth Factor-exposed Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[37]  J. Isner,et al.  Mouse model of angiogenesis. , 1998, The American journal of pathology.